Versikine also enhances the generation of CD103+CD11c+MHCII+ cDCs from Flt3L-mobilized primary bone marrow-derived progenitors, suggesting that Versican proteolysis may promote differentiation of tumor-seeding DC precursors toward IRF8- and BATF3-expressing cDCs in a mouse model (67). The gene discussed is FLT3LG; the disease is neoplasm.